Literature DB >> 23116901

[Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis].

Anna Serrano-Mollar1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive accumulation of extracellular matrix and an imbalance between profibrotic and antifibrotic mediators. In the last few years, understanding of the mechanisms of the biology of IPF has increased. One of the most significant discoveries is the finding that alveolar epithelial cell injury plays an important role in the pathogenesis of this disease. In this review, we describe some of the mechanisms involved in alveolar cell injury and their contribution to the development of IPF.
Copyright © 2012 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23116901      PMCID: PMC7131261          DOI: 10.1016/S0300-2896(12)70044-3

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  323 in total

1.  Lung volume reduction therapies for advanced emphysema: an update.

Authors:  Robert L Berger; Malcolm M Decamp; Gerard J Criner; Bartolome R Celli
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

2.  Spirometry for chronic obstructive pulmonary disease case finding in primary care?

Authors:  Homer Boushey; Paul Enright; Jonathan Samet
Journal:  Am J Respir Crit Care Med       Date:  2005-12-15       Impact factor: 21.405

3.  Tiotropium bromide step-up therapy for adults with uncontrolled asthma.

Authors:  Stephen P Peters; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren Denlinger; Linda L Engle; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Eugene R Bleecker
Journal:  N Engl J Med       Date:  2010-09-19       Impact factor: 91.245

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 5.  Cough and sputum production as risk factors for poor outcomes in patients with COPD.

Authors:  Marc Miravitlles
Journal:  Respir Med       Date:  2011-02-25       Impact factor: 3.415

6.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

Authors:  G Boyd; A H Morice; J C Pounsford; M Siebert; N Peslis; C Crawford
Journal:  Eur Respir J       Date:  1997-04       Impact factor: 16.671

Review 7.  Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.

Authors:  R G Barr; J Bourbeau; C A Camargo; F S F Ram
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

Review 8.  Domiciliary oxygen for chronic obstructive pulmonary disease.

Authors:  J M Cranston; A J Crockett; J R Moss; J H Alpers
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

9.  Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study.

Authors:  P Yin; C Q Jiang; K K Cheng; T H Lam; K H Lam; M R Miller; W S Zhang; G N Thomas; P Adab
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

10.  Physical activity in patients with COPD.

Authors:  H Watz; B Waschki; T Meyer; H Magnussen
Journal:  Eur Respir J       Date:  2008-11-14       Impact factor: 16.671

View more
  2 in total

Review 1.  The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.

Authors:  Ana Camelo; Rebecca Dunmore; Matthew A Sleeman; Deborah L Clarke
Journal:  Front Pharmacol       Date:  2014-01-10       Impact factor: 5.810

2.  The gut-lung axis: Gut microbiota changes associated with pulmonary fibrosis in mouse models induced by bleomycin.

Authors:  Yunyun Quan; Zhujun Yin; Shilong Chen; Jirui Lang; Liyang Han; Jing Yi; Lu Zhang; Qianhua Yue; Weiwei Tian; Ping Chen; Shenglin Du; Jianbo Wang; Ying Dai; Hua Hua; Jin Zeng; Li Li; Junning Zhao
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.